A detailed history of Moors & Cabot, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Moors & Cabot, Inc. holds 3,739 shares of VRTX stock, worth $1.88 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
3,739
Previous 3,940 5.1%
Holding current value
$1.88 Million
Previous $1.65 Million 6.44%
% of portfolio
0.09%
Previous 0.09%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $78,954 - $97,591
-201 Reduced 5.1%
3,739 $1.75 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $19,161 - $20,965
47 Added 1.21%
3,940 $1.65 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $144,746 - $173,306
-422 Reduced 9.78%
3,893 $1.58 Million
Q3 2023

Nov 07, 2023

SELL
$338.18 - $362.46 $63,916 - $68,504
-189 Reduced 4.2%
4,315 $1.5 Million
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $129,541 - $144,986
412 Added 10.07%
4,504 $1.59 Million
Q1 2023

May 04, 2023

SELL
$283.23 - $323.1 $54,946 - $62,681
-194 Reduced 4.53%
4,092 $1.29 Million
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $324,051 - $364,558
1,134 Added 35.98%
4,286 $1.24 Million
Q4 2022

Feb 06, 2023

SELL
$285.76 - $321.48 $267,471 - $300,905
-936 Reduced 22.9%
3,152 $910,000
Q3 2022

Nov 07, 2022

BUY
$273.83 - $305.53 $6,298 - $7,027
23 Added 0.57%
4,088 $1.18 Million
Q2 2022

Aug 08, 2022

BUY
$234.96 - $292.55 $42,762 - $53,244
182 Added 4.69%
4,065 $1.15 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $155,215 - $182,939
701 Added 22.03%
3,883 $1.01 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $4.75 Million - $5.99 Million
-26,818 Reduced 89.39%
3,182 $699,000
Q3 2021

Nov 05, 2021

BUY
$181.39 - $202.99 $5.44 Million - $6.09 Million
30,000 New
30,000 $29,000
Q1 2021

May 12, 2021

SELL
$207.02 - $241.31 $339,926 - $396,231
-1,642 Closed
0 $0
Q4 2020

Feb 11, 2021

SELL
$207.01 - $276.09 $33,949 - $45,278
-164 Reduced 9.08%
1,642 $387,000
Q3 2020

Nov 09, 2020

SELL
$255.65 - $303.1 $55,987 - $66,378
-219 Reduced 10.81%
1,806 $491,000
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $10,597 - $13,902
47 Added 2.38%
2,025 $591,000
Q1 2020

May 12, 2020

SELL
$199.77 - $247.81 $57,134 - $70,873
-286 Reduced 12.63%
1,978 $474,000
Q4 2019

Jan 28, 2020

BUY
$166.71 - $223.91 $377,431 - $506,932
2,264 New
2,264 $496,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.